| Document |
Document Title |
|
WO/2021/140488A1 |
A method for preparing a bovine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Bos taurus myoglobin MYG; constructing a first E...
|
|
WO/2021/139756A1 |
The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline de...
|
|
WO/2021/140489A1 |
A method for preparing a porcine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Sus scrofa myoglobin MYG; constructing a first ...
|
|
WO/2021/141506A1 |
The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small mo...
|
|
WO/2021/142171A1 |
Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising sub...
|
|
WO/2021/141066A1 |
The present invention pertains to a platelet aggregator that contains amorphous polyphosphoric acid as an active ingredient, wherein the polyphosphoric acid is a Ca salt of polyphosphoric acid. The platelet aggregator acts on damaged gas...
|
|
WO/2021/136390A1 |
A blood coagulation factor XIa inhibitor of formula I, a pharmaceutical composition containing same, a preparation method therefor, and use thereof in preparation of drugs for prevention or treatment of thrombosis and embolism-related di...
|
|
WO/2021/135071A1 |
Disclosed is a use of piperazine ferulate tablets in the preparation of medicaments for preventing and treating anemia. The piperazine ferulate tablets can obviously improve the content of erythropoietin and further promote bone marrow t...
|
|
WO/2021/132661A1 |
The present invention relates to a method of constructing a library that includes two or more types of cyclic peptides, involving: a step for preparing an mRNA library that codes peptides which include a sequence represented in formula (...
|
|
WO/2021/132627A1 |
The present invention addresses the problem of providing a culturing method and a production method for hematopoietic stem cells which can be used for hematopoietic stem cell transplantation. The method for culturing hematopoietic stem c...
|
|
WO/2021/133660A1 |
Provided are methods for clinical treatment of pregnancy-associated atypical haemolytic uraemic syndrome (p-aHUS), including postpartum aHUS, using an anti-C5 antibody, or antigen binding fragment thereof, such as ravulizumab (ULTOMIRIS®).
|
|
WO/2021/133874A1 |
Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.
|
|
WO/2021/123799A1 |
The invention relates to red blood cell-derived vesicles comprising encapsulated active agents, their use in therapy and methods of production thereof.
|
|
WO/2021/127525A1 |
This disclosure relates to pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are dosage regimens for such antibodies or antigen-binding f...
|
|
WO/2021/124172A1 |
The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in th...
|
|
WO/2021/121396A1 |
Provided is a tricyclic plasma kallikrein inhibitor compound having a novel structure, good activity and high selectivity, which can be widely used in the prevention or treatment of diseases related to a plasma kallikrein activity.
|
|
WO/2021/124272A1 |
The present application discloses a compound of formula (I) or a salt thereof: (I) and compositions comprising such compound or salt thereof. The use of such compound, salt thereof or composition comprising same for treating anemia or le...
|
|
WO/2021/123090A1 |
Expression of lambda antibody light chain with non-native leader sequence, wherein light chain is sequence-engineered to restore native N terminus. Immunoglobulin lambda variable domain sequence comprising N terminal deletion for express...
|
|
WO/2021/125474A1 |
Edoxaban p-toluenesulfonate monohydrate that is currently on the market has problems of having very poor crystallinity, being unstable due to moisture, being a pale yellow solid in terms of solid color, and being not easy to tablet durin...
|
|
WO/2021/125291A1 |
The present disclosure provides a novel thrombin action inhibitor, a composition for preventing skin disorders caused by pollens, and a cosmetic or non-therapeutic method for preventing skin disorders caused by pollens. More specifically...
|
|
WO/2021/123033A1 |
The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four α-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming α-helices t...
|
|
WO/2021/125345A1 |
Provided is a vasodilator that can dilate a blood vessel even in an environment where ROS are present. This vasodilator includes the compound represented by formula (1) or a salt thereof. In formula (1), ring A and ring B may be the sa...
|
|
WO/2021/120376A1 |
A composite probiotic composition having an anti-aging effect and a preparation method therefor and an application thereof. The composition comprises: 1-10 parts of Bifidobacterium, 1-10 parts of Lactobacillus bulgaricus, 1-10 parts of S...
|
|
WO/2021/115465A1 |
An isolated monoclonal antibody that specifically binds human RANKL, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a me...
|
|
WO/2021/113974A1 |
Multivalent anti-platelet glycoprotein l(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein l(b)alpha and lacking a Fc portion, therefore do not in...
|
|
WO/2021/119040A1 |
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
|
|
WO/2021/119189A1 |
The present invention relates to compositions and methods for identifying at-risk patients and modulating thrombotic conditions in a cancer patient. Embodiments provided herein include a method of determining risk for a thrombotic event ...
|
|
WO/2021/115886A1 |
An isolated recombinant soluble endothelial cell protein C receptor (r-sEPCR) for use as a hemostatic agent.
|
|
WO/2021/108862A1 |
The present invention relates to an anti-FXII antibody for use in a method of treating or preventing hereditary angioedema (HAE) in a subject, wherein the antibody is administered subcutaneously to the subject.
|
|
WO/2021/110127A1 |
A method for treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hemoglobin to the subject.
|
|
WO/2021/113696A1 |
The present application provides for a method for controlling coagulation in a subject in need of extracorporeal membrane oxygenation. The method comprises administering an effective amount of an anticoagulant agent that directly inhibit...
|
|
WO/2021/113682A1 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
|
|
WO/2021/110959A1 |
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of...
|
|
WO/2021/113765A1 |
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enh...
|
|
WO/2021/109979A1 |
Provided are compositions comprising: (i) a blend of fibrinogen, thrombin, wherein the blend is in the form of a plurality of particles, and (ii) a hydrophobic dispersant, wherein the composition is in the form of a paste at at-least one...
|
|
WO/2021/110076A1 |
The present invention belongs to the field of medicinal chemistry and relates to oxamide derivatives, a preparation method therefor and the use thereof in medicine. In particular, provided is a compound of formula (I) or a stereoisomer, ...
|
|
WO/2021/113800A1 |
Factor VIII variants and methods of use thereof are disclosed. In accordance with the present invention, compositions and methods for the modulation of hemostasis in patients in need thereof are provided. More specifically. Factor VIII (...
|
|
WO/2021/110942A1 |
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising maltose and isomalt as diluents. The invention further relates to the us...
|
|
WO/2021/112597A1 |
The present invention relates to a pharmaceutical composition for treating diabetic retinopathy. According to the present invention, the pharmaceutical composition can treat diabetic retinopathy by means of a single administration and th...
|
|
WO/2021/112207A1 |
The present invention provides a means for treating a symptom of cerebral infarction in a cerebral infarction patient, particularly in an acute stage cerebral infarction patient, without causing undesirable side effects, by optimizing th...
|
|
WO/2021/113686A1 |
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
|
|
WO/2021/104353A1 |
The present invention relates to a crystal form of a quinolinone compound and a use thereof. The present invention further relates to a pharmaceutical composition comprising the crystal form, and a use of the crystal form or the pharmace...
|
|
WO/2021/107125A1 |
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on LPA3. As a result of having performed thoroughgoing studies, the inventors perfected the p...
|
|
WO/2021/104427A1 |
A crystalline form A of a nitrogen-containing tricyclic compound shown in formula (I), a pharmaceutical composition comprising the crystalline form A, and the use of the crystalline form A or the pharmaceutical composition in the prepara...
|
|
WO/2021/106988A1 |
It was found that a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has potent G9a inhibitory activity. Because of the ability to inhibit G9a, the compound (I) or a pharmaceutically acceptable sa...
|
|
WO/2021/107117A1 |
A method for producing a hematopoietic cell from a pluripotent stem cell, the method including a first step for culturing naïve pluripotent stem cells and inducing differentiation into yolk sac cells, a second step for culturing primed ...
|
|
WO/2021/105389A1 |
Antibodies to the enzyme matriptase‐2 (MTP‐2) are presented. Inhibiting MTP‐2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine pr...
|
|
WO/2021/107835A1 |
The present invention provides an oral pharmaceutical composition comprising iron succinate for use in treating iron deficiency in a subject diagnosed with heart failure (HF) with reduced ejection fraction (HFrEF), and a method for treat...
|
|
WO/2021/108806A1 |
Compositions, containers and kits for low temperature storage of a specified quantity of packed red blood cells (RBCs) include L-camitine, HES and blood plasma proteins. Methods of storing a packed RBC blood product, transfusing a packed...
|
|
WO/2021/105137A1 |
Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolys...
|
